Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae.
about
Recombinant Flagellin-Porcine Circovirus Type 2 Cap Fusion Protein Promotes Protective Immune Responses in MiceImmunity Elicited by an Experimental Vaccine Based on Recombinant Flagellin-Porcine Circovirus Type 2 Cap Fusion Protein in PigletsInduction of a robust immunity response against novel duck reovirus in ducklings using a subunit vaccine of sigma C proteinImproved Production Efficiency of Virus-Like Particles by the Baculovirus Expression Vector SystemDelivery strategies for novel vaccine formulations.Potential of recombinant inorganic pyrophosphatase antigen as a new vaccine candidate against Baylisascaris schroederi in miceMemory T cell proliferative responses and IFN-γ productivity sustain long-lasting efficacy of a Cap-based PCV2 vaccine upon PCV2 natural infection and associated disease.Insect cell technology is a versatile and robust vaccine manufacturing platform.Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens.Best practice and future challenges for vaccination against porcine circovirus type 2.Recombinant expression of beak and feather disease virus capsid protein and assembly of virus-like particles in Nicotiana benthamiana.Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania.Secreted Expression of the Cap Gene of Porcine Circovirus Type 2 in Classical Swine Fever Virus C-Strain: Potential of C-Strain Used as a Vaccine Vector.Porcine circovirus 2 immunology and viral evolution.
P2860
Q27304664-DA6E36EE-3157-4FF8-9086-D220AF3CC8F6Q27326717-004D0972-829F-4897-87A8-816A401EFB60Q30832016-9227C89E-4B37-4B8C-8E2B-7BAF11CBF09FQ35803488-827DAD36-209B-45D2-B527-3201721A5DA7Q37195521-397706DD-8D50-406E-9EF7-A549104CB0CEQ37364964-FC7610D9-FD5F-4BE4-9205-0B8A936011F4Q37723618-9EC1C137-284B-4AE1-97F8-F8AB4B0CFAB0Q37909427-71F7FD08-6869-4829-B1D6-2C8F95ABB540Q38243160-65663EF4-06D7-40BF-B873-3C26F173AD21Q38268599-B9B053A4-9D23-450C-8A4A-0AD9CFE32F33Q40047200-CDB78E5B-1C43-4287-924B-9493F234DC40Q41404819-A414AA24-6E86-45A9-BAC0-B6E553CE9C18Q43861583-1A1C152A-479B-4384-9516-21CED6E9467DQ50938133-15E7AB88-40CB-494C-8376-647F60A4B9E2
P2860
Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Immunity conferred by an exper ...... sed in Trichoplusia ni-larvae.
@en
Immunity conferred by an exper ...... sed in Trichoplusia ni-larvae.
@nl
type
label
Immunity conferred by an exper ...... sed in Trichoplusia ni-larvae.
@en
Immunity conferred by an exper ...... sed in Trichoplusia ni-larvae.
@nl
prefLabel
Immunity conferred by an exper ...... sed in Trichoplusia ni-larvae.
@en
Immunity conferred by an exper ...... sed in Trichoplusia ni-larvae.
@nl
P2093
P50
P1433
P1476
Immunity conferred by an exper ...... ssed in Trichoplusia ni-larvae
@en
P2093
Fernando Rodríguez
José M Escribano
María Fort
Miquel Nofrarías
Sherry Kurtz
P304
P356
10.1016/J.VACCINE.2009.12.061
P407
P577
2010-01-05T00:00:00Z